文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

调理素肽MOP3减轻缺血性急性肾损伤

Opsonic Peptide MOP3 Attenuates Ischemic Acute Kidney Injury.
PubMed 文献 · Shock · 2026-10-13
一句话结论小鼠肾缺血再灌注模型中,再灌注起始给予MOP3可降低循环eCIRP 40%、改善肾功能指标并减轻肾小管损伤与细胞死亡。

该研究为小鼠肾缺血再灌注(I/R)诱导AKI模型,双侧肾缺血30分钟后于再灌注起始给予MOP3或溶媒,20小时后取材评估。MOP3使循环eCIRP降低40%,肾IL-6、IL-1β、MIP-2、KC mRNA分别降低43%、84%、73%、69%;血清尿素氮、肌酐、NGAL分别降低56%、63%、44%;肾KIM-1与NGAL mRNA降低88%与44%,蛋白降低29%与45%;并减轻肾小管损伤、减少TUNEL阳性细胞。提示MOP3可能成为缺血性AKI的候选治疗策略,但尚属动物实验。

要点

  • 小鼠双侧肾缺血30分钟后于再灌注起始给予MOP3,20小时后循环eCIRP较溶媒组降低40%。
  • MOP3组血清尿素氮、肌酐、NGAL分别较溶媒组降低56%、63%、44%,肾功能指标改善。
  • MOP3降低肾IL-6、IL-1β、MIP-2、KC mRNA 43%、84%、73%、69%,减轻炎症。
  • MOP3使肾KIM-1与NGAL mRNA降低88%与44%、蛋白降低29%与45%,并减少TUNEL阳性细胞。
  • 以上均为小鼠模型结果,原文未给出临床人群剂量、给药方案或安全性数据。

适用人群与场景

  • 小鼠肾缺血再灌注诱导AKI模型:双侧肾缺血30分钟后再灌注。
  • 原文未提及临床患者纳入或排除人群,也未提及急诊/ICU/院前具体场景。

诊断标准与关键阈值

  • 原文未提及临床诊断标准或启动/停止阈值;动物模型采用双侧肾缺血30分钟后再灌注造模。

处置流程与药物剂量

  • 动物实验中于再灌注起始给予MOP3或溶媒,20小时后采集血与肾组织评估。
  • 原文未提及MOP3的剂量、单位、给药途径、频次或疗程,也未提及目标值。

红旗征与不能漏的情况

  • 原文未提及红旗征或需要立刻处理/不能漏诊的情况。

研究设计与关键结果

  • 研究类型为小鼠在体实验(非临床研究),样本量与中心数原文未提及;人群为肾I/R诱导AKI小鼠。
  • 干预为再灌注起始给予MOP3,对照为溶媒;主要终点原文未明确标注。
  • MOP3使循环eCIRP降低40%,肾IL-6、IL-1β、MIP-2、KC mRNA分别降低43%、84%、73%、69%。
  • MOP3使血清尿素氮、肌酐、NGAL分别降低56%、63%、44%。
  • MOP3使肾KIM-1与NGAL mRNA降低88%与44%,蛋白降低29%与45%,并减轻肾小管损伤、减少TUNEL阳性细胞。

证据类型、等级与局限

  • 证据类型:动物实验(小鼠肾I/R AKI模型);原文未给出证据等级或推荐强度。
  • 局限:原文未提及样本量、盲法、随机化细节;结论为初步临床前探索,尚需进一步验证。

对床旁实践的改变

  • 该内容暂不改变急诊/ICU现有缺血性AKI处理:仅为小鼠临床前结果,无人体剂量、给药途径或疗效安全性数据。
  • 适用与不适用人群原文未提及;常见陷阱是把动物模型中的相对降幅误当作临床决策阈值。

指南或共识出处

  • 原文未提及指南或共识出处;文献来源为PubMed收录的Shock杂志研究。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Renal ischemia/reperfusion (I/R) induced acute kidney injury (AKI) is a common and serious condition characterized by renal dysfunction, inflammation, tubular injury, and cell death. Extracellular cold-inducible RNA-binding protein (eCIRP) is a damage-associated molecular pattern that contributes to inflammation and tissue injury. MFG-E8-derived oligopeptide 3 (MOP3) is an opsonic peptide that binds eCIRP and promotes its phagocytic clearance. Here, we investigated the therapeutic effects of MOP3 in a murine model of renal I/R-induced AKI.

METHODS: Mice were subjected to 30 minutes of bilateral renal ischemia and treated with MOP3 or vehicle at the onset of reperfusion. Blood and kidney tissues were collected 20 h later. Renal inflammation, kidney function, tubular injury markers, histological damage, and cell death were assessed by RT-qPCR, biochemical assays, Western blotting, hematoxylin and eosin staining, and TUNEL staining.

RESULTS: MOP3 treatment reduced circulating eCIRP by 40% and renal IL-6, IL-1β, MIP-2, and KC mRNA expression by 43%, 84%, 73%, and 69%, respectively, compared with vehicle treatment. Serum urea nitrogen, creatinine, and NGAL levels were reduced by 56%, 63%, and 44%, respectively, after MOP3 treatment. MOP3 also decreased renal KIM-1 and NGAL mRNA expression by 88% and 44% and reduced their protein levels by 29% and 45%, respectively. Furthermore, MOP3 attenuated renal tubular injury and decreased TUNEL-positive cells.

CONCLUSIONS: These findings demonstrate that MOP3 attenuates inflammation, renal dysfunction, tubular injury, and cell death following renal I/R, suggesting that MOP3 may represent a promising therapeutic strategy for ischemic AKI.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Tenet M, Jin H, Aziz M, et al. Opsonic Peptide MOP3 Attenuates Ischemic Acute Kidney Injury. Shock. 2026. PMID: 42868069. doi:10.1097/SHK.0000000000002949

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。